Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
Merck
Medtronic
Baxter

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR ROCURONIUM BROMIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rocuronium Bromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00124722 ↗ A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia Completed Merck Sharp & Dohme Corp. Phase 3 2004-12-01 The primary purpose of this study is to evaluate the time course of muscle relaxation after administration of three different single intravenous bolus doses of rocuronium bromide for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) in term neonates (birth to <28 days old), infants (28 days to <=3 months) and toddlers (>3 months to <=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age). Subjects in each of the age groups will be randomized to one of 3 Zemuron® doses: 0.45 mg/kg, 0.6 mg/kg, or 1.0 mg/kg.
NCT00124735 ↗ A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797) Completed Merck Sharp & Dohme Corp. Phase 3 2004-10-01 The primary purpose of this study is to determine the dose requirements of rocuronium bromide when administered as a bolus dose (a single, large dose) for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) and when administered by either continuous infusion or bolus doses for maintenance of muscle relaxation in term neonates (birth to <28 days old), infants (28 days to <=3 months) and toddlers (>3 months to <=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age).
NCT00421148 ↗ Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961) Completed Merck Sharp & Dohme Corp. Phase 3 2005-05-30 The purpose of this study is: - to explore the dose-response relation of sugammadex (Org 25969, MK-8616, SCH 900616) given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in pediatric and adult participants - to explore the pharmacokinetics (PK) of sugammadex in pediatric and adult participants, and to evaluate the safety of sugammadex in pediatric and adult participants.
NCT00535743 ↗ Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) Completed Merck Sharp & Dohme Corp. Phase 2 2004-03-04 The objective of this trial was to explore the dose-response relation of sugammadex (Org 25969; MK-8616) administered for the reversal of neuromuscular blockade (NMB) at 3 and 15 minutes following administration of 1.0 and 1.2 mg/kg of Esmeron® (rocuronium) in participants receiving surgery, classified as American Society of Anesthesiologists (ASA) class 1 (otherwise normal, healthy participant), class 2 (participant with mild systemic disease), or class 3 (participant with a severe systemic disease that limits activity, but is not incapacitating).
NCT00559468 ↗ Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028) Completed Merck Sharp & Dohme Corp. Phase 3 2006-12-07 The objective of the trial was to show equivalence in recovery from neuromuscular block after a single dose of 4.0 mg/kg sugammadex, administered at first twitch (T1) 3-10% after continuous infusion of rocuronium, between participants receiving maintenance anesthesia using propofol and participants receiving sevoflurane, to investigate the safety and to compare the plasma levels of rocuronium in participants after continuous infusion of rocuronium and before the administration of sugammadex, under either propofol or sevoflurane anesthesia.
NCT00656799 ↗ Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773) Completed Merck Sharp & Dohme Corp. Phase 3 2008-04-01 The clinical trial objectives were to evaluate the dialysability of the sugammadex-rocuronium complex; it's safety and efficacy in participants with severe renal impairment.
NCT00675792 ↗ Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4 Completed Merck Sharp & Dohme Corp. Phase 3 2008-05-01 The primary purpose of this study is to compare the incidence of residual neuromuscular blockade at the time of tracheal extubation after reversal of rocuronium bromide-induced neuromuscular blockade by 4 mg/kg sugammadex with that of 50 µg/kg neostigmine. Residual neuromuscular blockade is defined as the fourth twitch to first twitch (T4/T1) ratio of < 0.90.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rocuronium Bromide

Condition Name

Condition Name for Rocuronium Bromide
Intervention Trials
Anesthesia 9
Neuromuscular Blockade 9
Anesthesia, General 3
Muscle Relaxation 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rocuronium Bromide
Intervention Trials
Pain, Postoperative 3
Neoplasms 2
Pneumoperitoneum 2
Muscle Hypotonia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rocuronium Bromide

Trials by Country

Trials by Country for Rocuronium Bromide
Location Trials
United States 30
Netherlands 5
Turkey 5
Austria 3
Belgium 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rocuronium Bromide
Location Trials
Texas 3
Missouri 3
Wisconsin 2
Tennessee 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rocuronium Bromide

Clinical Trial Phase

Clinical Trial Phase for Rocuronium Bromide
Clinical Trial Phase Trials
Phase 4 15
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rocuronium Bromide
Clinical Trial Phase Trials
Completed 32
Unknown status 9
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rocuronium Bromide

Sponsor Name

Sponsor Name for Rocuronium Bromide
Sponsor Trials
Merck Sharp & Dohme Corp. 17
Ain Shams University 3
Seoul National University Hospital 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rocuronium Bromide
Sponsor Trials
Other 39
Industry 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Express Scripts
Colorcon
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.